GA
BLUE

Geneva Advisors’s bluebird bio BLUE Stock Holding History

Geneva Advisors’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$337K Buy
+247
New +$298K 0.01% 585

Other funds holding BLUE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Geneva Advisors's BLUE Position: Q2 2017 in Review

Geneva Advisors opened a new position in bluebird bio (BLUE) in Q2 2017: 247 shares worth $337K. The stake represents 0.01% of the portfolio and ranks #585 among its holdings.

241 funds tracked by Wall St. Rank hold BLUE as of Q2 2017.

  • Geneva Advisors held 247 shares of bluebird bio worth $337K as of Q2 2017.
  • bluebird bio was a new Geneva Advisors position in Q2 2017.
  • bluebird bio made up 0.01% of Geneva Advisors's portfolio in Q2 2017, its #585 holding.
  • 241 funds tracked by Wall St. Rank held bluebird bio as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.